Subscribe
ericsphotography-istockphoto-com-us-gavel-2-1
ericsphotography / iStockphoto.com
15 October 2018Americas

Federal Circuit upholds two patent decisions over Copaxone

The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone (glatiramer acetate) 40mg/mL treatment are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Alvogen launches Copaxone generic
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Big Pharma
EPO upholds Copaxone patent
28 May 2014   Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Big Pharma
Alvogen launches Copaxone generic
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Big Pharma
EPO upholds Copaxone patent
28 May 2014   Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.

More on this story

Big Pharma
Alvogen launches Copaxone generic
6 September 2016   Pharmaceutical company Alvogen has launched the first generic version of Copaxone in Europe under the name Remurel.
Big Pharma
EPO upholds Copaxone patent
28 May 2014   Teva has successfully defended a patent for its multiple sclerosis drug Copaxone (glatiramer acetate) in Europe.

More features

Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university
Novartis loses cancer drug patent following Teva challenge at EPO
A step too far? Why Stewart’s approach is dividing opinion
WATCH: Section 112—Where has the dust settled?